Novo Nordisk announced a partnership with OpenAI to apply advanced artificial‑intelligence models across its drug discovery, manufacturing, and commercial operations, with a focus on obesity and diabetes treatments.
The collaboration is a strategic response to growing competition in the GLP‑1 market, particularly from Eli Lilly’s tirzepatide and other emerging therapies. By integrating OpenAI’s AI capabilities, Novo aims to shorten development timelines, lower costs, and maintain its leadership in metabolic disease treatment.
"This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare," said Mike Doustdar, President and CEO. "Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever." Sam Altman, CEO of OpenAI, added, "AI is reshaping industries and in life sciences, it can help people live better, longer lives. This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations, and redefine the future of patient care."
Pilot programs are launching immediately, with full integration of OpenAI tools expected by the end of 2026. The partnership also includes upskilling Novo’s global workforce in AI literacy, positioning the company to leverage data at scale across its research and commercial functions.
Novo’s Q4 2025 earnings, released on February 3, 2026, showed an EPS of $1.01 versus analyst expectations of $0.90 and revenue of $12.43 billion, up 11.1% year‑over‑year. Management guided for 2026 adjusted sales and profit growth down 5% to 13% at constant exchange rates, citing U.S. pricing pressures and loss of exclusivity in some markets. The partnership is expected to help offset these headwinds by accelerating pipeline development and improving operational efficiency.
Shares rose 2.8% after the announcement, reflecting investor confidence that the AI collaboration will strengthen Novo’s competitive position against rivals such as Eli Lilly, whose Q4 2025 revenue of $19.29 billion grew 42.6% year‑over‑year.
The partnership positions Novo Nordisk to maintain its leadership in obesity and diabetes treatment, while also providing a strategic tool to counter the competitive threat posed by Eli Lilly’s tirzepatide and other emerging therapies. The collaboration marks a significant shift toward technology‑driven drug development and could reshape Novo’s long‑term growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.